Israel state records י"ב באדר התשס"ו March 12, 2006
Download 0.86 Mb.
|
- Navigate this page:
- 134735 [21][11] ראש קרבי שובר קירות
- 134910 [21][11] ארוסול LIPOSOME
- 135069 [21][11] שיטה ומערכת לחותמות זמן ספרתיות בעלות מפתח זמני
- 135210 [21][11] ¹N – [2,2 – דימתיל 1S – (
- תכשירי רוקחות המכילים תרכובת זו ושימוש בה להכנת תרופות
- נגזרות ציקלופנטן ותכשירי רוקחות המכילים אותן לטיפול באי סדרים הקשורים בקולטן המוטילין
- 135920 [21][11] תולדת 2 – – אריל – 8 – אוקסודיהדרופורין
- 2 - ARYL - 8 - OXODIHYDROPURINE DERIVATIVE, PROCESS FOR THE PREPARATION THEREOF, PHARMACEUTICAL COMPOSITION CONTAINING THE SAME AND INTERMEDIATE THEREFOR
| [57] A process for preparing compounds of the formula 
in which R* is hydrogen or (C1-C4) – alkyl, or salts thereof with acids or bases, which comprises (a) (Step 1) reacting a trivalent methylphosphorus compound of the formula (II), with an unsaturated derivative of the formula (III), in the presence of a condensing agent or activator from the group consisting of carboxylic anhydrides and, if appropriate, alcohols, to give an adduct (IV),
where in the formulae R1 and R2 independently of one another are (C1-C18) alkoxy with or without substitution, benzyloxy or phenoxy, which may also be substituted, or one of the radicals R1 and R2 is hydroxyl, and R* is as defined in formula (I), (b) Step 2) the adduct (IV) is, if appropriate after hydrolysis to aldheydes (R* = H) or ketones (R* = alkyl) of the formula (IV'), or to a salt thereof 
in which Z is OH, R1 or R2, reacted under the conditions of a Strecker synthesis with ammonia/ammonium chloride and sodium cyanide or alternatively with mixtures of ammonia and hydrocyanic acid or with ammonia and a salt of hydrocyanic acid, if appropriate in the presence of ammonium chloride, to give the α-aminonitriles of the formula (V) or a salt thereof, 
where in the formula (IV') and (V) the radical R* is as defined in formula (I) and Z is as defined in formula (IV') or is OH, and (c) (Step 3) the compound of the formula (V) is hydrolyzed under acidic or basic conditions to give the compound of the formula (I) or salts thereof.
__________
[57] A wall breaching warhead (10) for forming a hole through a brick wall, the warhead comprising: (a) a shaped charge (12) of explosive material having a central axis, said charge having a front surface including; (i) a central portion (16) adjacent to said central axis having a generally convexly-curved shape, and (ii) an annular portion (18) circumscribing said central portion, said annular portion having a generally concavely-curved shape; and (b) a metallic liner (2) adjacent to at least said annular portion of said front surface, wherein said annular portion and said metallic liner are configured such that, on detonation of said charge, a major part of the material from said metallic liner is concentrated into an expanding conical path diverging from said central axis at an angle of between 30o and 60o.
__________
[57] A lipsome for delivery of an aqueous dispersion of an anti-cancer drug via small particle aerosol, said liposome comprising the anti-cancer drug, said anti-cancer drug selected from the group consisting of taxol and taxol-A; and a lipid suitable for solubilization and delivery of the anticancer drug via said small particle aerosol, wherein the ratio of said anti-cancer drug to lipid is about 1:1 to about 1:2000 wt:wt and wherein the final concentration of said anti-cancer drug in said liposome is no greater than 5.0 mg/ml. __________
[57] A method for certifying data, comprising the steps of: generating a key pair at a first time interval, the key pair including a private key and a public key; receiving a certification request; determining if the certification request was received within the first time interval; if the certification request was received within the first time interval, automatically responding to the certification request by digitally signing data associated with the certification request using the private key; and deleting the private key. __________
[57] N1-[2,2-dimethyl-1S-(pyridin-2-ylcarbamoyl)-propyl]-N4-hydroxy-2R-isobutyl-3S-methoxy-succinamide, of the formula 
or a pharmaceutically acceptable salt, hydrate or solvate thereof. __________
[57] A compound of the formula 
wherein R1 is selected from hydrogen, C1-5 alkyl, substituted C1-5 alkyl (where the alkyl substituents are one or more halogens), RaRbN-C1-5 alkyl (where the Ra and Rb are independently selected from hydrogen and C1-5 alkyl, or are taken together to form a morpholine, piperazine, piperidine, or N-substituted piperidine where the N-substituent is C1-5 alkyl or phenyl C1-5 alkyl), C1-5 alkylcarbonyl, C1-5 alkoxycarbonyl, aminocarbonyl, C1-9 alkylaminocarbonyl, cyclo C3-9 alkylaminocarbonyl, pyridinylcarbonyl, substituted pyridinylcarbonyl (where the pyridinyl substituents are selected from the group consisting of one or more halogens and C1-5 alkyl), thiophenecarbonyl, substituted thiophenecarbonyl (where the thiophene substituents are selected from the group consisting of one or more halogens and C1-5 alkyl), phenyl, phenyl C1-5 alkyl, phenoxycarbonyl, phenylcarbonyl, diphenylmethylcarbonyl, phenylaminocarbonyl, phenylthiocarbonyl, phenylaminothiocarbonyl, substituted phenyl, substituted phenyl C1-5 alkyl, substitued phenoxycarbonyl, substituted phenylcarbonyl, substituted phenylaminocarbonyl, substituted diphenylmethylcarbonyl, substituted phenylthiocarbonyl, and substituted phenylaminothiocarbonyl (where the phenyl substituents are selected from the group consisting of one or more of halogen, C1-5 alkyl, trihalomethyl, C1-5 alkoxy, amino, nitrile, nitro, C1-5 alkylamino, di-C1-5 alkylamino, if there are more than one substitutent they may be taken together with the phenyl ring to form a fused bicyclic 7-10 membered heterocyclic ring having one ot two heteroatoms selected from oxygen, sulfur or nitrogen or the substituents may be taken together to form a fused bicyclic 7-10 membered aromatic ring; R2 is selected from hydrogen, C1-5 alkyl, C1-5 alkoxy, phenyl, substituted phenyl (where the phenyl subsitutents are selected from one or more of the group consisting of halogen and C1-5 alkyl), phenyl C1-5 alkyl, substituted phenyl C1-5 alkyl ( where the phenyl substituents are selected from one or more of the group consisting of halogen, C1-5 alkyl, C1-5 alkoxy, halo, and di-C1-5 alkylamino), R3 is selected from hydrogen, C1-5 alkylcarbonyl, substituted C1-5 alkylcarbonyl (where the alkyl substituents are selected from one or more halogens), phenylcarbonyl, and substituted phenylcarbonyl (where the phenyl substituents are selected from one or more of the group consisting of halogen, C1-5 alkyl, C1-5 alkoxy, amino, C1-5 alkylamino, and di-C1-5 alkylamino); R4 is selected from hydrogen, C1-5 alkylcarbonyl, substituted C1-5 alkyl carbonyl (where the alkyl subsitutents are selected from one or more halogens), phenylcarbonyl, and substituted phenylcarbonyl (where the phenyl substituents are selected from one or more of the group consisting of halogen, C1-5 alkyl, C1-5 alkoxy, amino, C1-5 alkylamino, and di-C1-5 alkylamino); n is 0-3; m is 1-5; R5 is X- (CH2)q-At where q is 0-2, t is 0-1; X is oxygen, CH2, sulfur, or NRc where Rc is hydrogen, C1-5 alkyl, morpholino C1-5 alkyl, piperidinyl C1-5 alkyl, N-phenylmethylpiperidinyl or piperazinyl C1-5 alkyl, with the proviso that if q and t are 0, then X is hydroxy, thiol, amino, or CH3, A is C1-5 alkoxycarbonyl, phenylcarbonyl, or R7R8N-where R7 is independently selected from hydrogen, C1-5 alkyl, cyclo C1-9 alkyl, or R7 is taken together with R8 to form a 5 or 6 membered heterocyclic ring with one or more heteroatoms selected from the group consisting of oxygen, nitrogen or sulfur and N-oxides thereof; R8 is independently selected from hydrogen, C1-5 alkyl, cyclo C1-9 alkyl or taken together with R7 to form a 5 or 6 membered heterocyclic ring with one or more heteroatoms selected from the group consisting of oxygen, nitrogen or sulfur, and N-oxides thereof; R6 is selected from hydrogen, halogen, C1-5 alkoxy, C1-5 alkylamino, or di-C1-5 alkylamino; and the pharmaceutically acceptable salts thereof. __________
Directory: Units -> RashamHaptentim -> Units -> patent -> yoman Units -> Perform and explain geodetic computations Units -> Demonstrate and apply advanced knowledge of programming techniques for electrotechnology Units -> Nzqa registered unit standard 22561 version 3 Units -> Nzqa registered unit standard 22528 version 2 Units -> Nzqa registered unit standard 26968 version 1 Units -> Nzqa registered unit standard 10212 version 5 Download 0.86 Mb. Share with your friends:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||